Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sangamo BioSciences
Biotech
Pfizer digs into gene editing with $300M Beam pact
Pfizer is taking a bigger bite out of the gene editing apple with $1.35 billion on the line for Beam Therapeutics' base editing tech.
Annalee Armstrong
Jan 10, 2022 6:00am
Sanofi tears up Sangamo deal in pivot to off-the-shelf approach
Jan 6, 2022 8:30am
Sangamo's Fabry gene therapy clears early clinical test
Nov 4, 2021 9:30am
Pfizer reveals series of delays to pivotal gene therapy readouts
Nov 3, 2021 8:25am
Sanofi hit by filing delays for key drugs
Oct 28, 2021 7:00am
In vivo gene editing grabs the spotlight after Intellia triumph
Sep 29, 2021 3:00am
